Do not read a blend as a single established medicine
CJC-1295 and ipamorelin are often discussed together in growth-hormone peptide marketing. They remain different substances. Before interpreting any comparison, establish the precise ingredient names, amount of each, route and whether the quoted vial is a single ingredient or a mixture. A total milligram figure can hide very different proportions.
Sources: FDA — compounding substances with potential safety risks, FDA — compounding questions and answers
Separate the safety observations
FDA describes limited clinical data and serious reported adverse events for CJC-1295, including increased heart rate and systemic vasodilatory reactions. Its ipamorelin discussion includes serious events in an intravenous study and insufficient information for other proposed routes. Those are specific evidence boundaries; they do not justify an invented rate of harm or a claim that a different route is proven safe.
Sources: FDA — compounding substances with potential safety risks, FDA — compounding questions and answers
The price cannot resolve the formulation
A cheaper vial could contain a different total amount, formulation or combination ratio. Even an accurate cost-per-milligram result would not establish equivalent exposure or a suitable prescription. No individualized injection schedule or blend conversion belongs in a price comparison. Laboratory documentation of identity, when available, would still be different from evidence of clinical benefit.
Sources: FDA — compounding substances with potential safety risks, FDA — compounding questions and answers
Why this profile has no purchase shortlist
This edition did not verify a sufficiently complete current clinical offer for a CJC-1295/ipamorelin blend. The omission is intentional: an unsupported price would make the record look more settled than it is. Use the FDA discussion to formulate questions for a qualified clinician, and distinguish a compounding nomination’s status from approval of a finished medicine.
Sources: FDA — compounding substances with potential safety risks, FDA — compounding questions and answers
Keep reading.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- FDA — compounding substances with potential safety risks ↗
Includes injectable GHK-Cu; route-specific concerns must not be applied indiscriminately to cosmetics. Regulatory page rechecked October 9, 2026; retain distinctions between approval, risk information and compounding nominations.
Checked October 9, 2026
- FDA — compounding questions and answers ↗
Clinical and regulatory context. A compounded preparation is not FDA-approved.
Checked October 8, 2026